Paclitaxel Production

Throughout the development of paclitaxel, one of the most successful anticancer drugs in the past 50 years, adequate supply has been a major challenge. This drug has been very complex to synthesize economically from first principles and cumbersome to isolate from natural sources. In addition, paclitaxel represents only a minor proportion of the total taxoid content of Taxus species.

The first commercial company to accomplish large-scale production of paclitaxel was Polysciences, Inc. Clinical trials were possible when a methodology was derived to extract a precursor of this drug, 10-deacetyl-baccatin III, from the common evergreen yew tree Taxus baccata, often found in people's gardens. By chemical synthesis procedures the precursor was subsequently converted to paclitaxel.

Methods of paclitaxel production

Since the discovery of paclitaxel, a sustainable increase of its extraction was the principal goal of the industry. A serious obstacle is the aforementioned low proportion of paclitaxel, even in the most productive species, Taxus brevifolia (0.001-0.05%). Consequently the treatment of one cancer patient consumes approximately eight 60-year old yew trees.

Similar situation is with other Taxus species as well, such as Taxus chinensis. According to the report from CEC China Pharmaceuticals Ltd., 10 thousand kg of leaves and bark from this species are required to isolate 1 kg of paclitaxel.

Advanced, expensive technology and complex purification techniques are needed for such extractions, which is the reason why ecological harvesting protocols are being developed. Atlantic Forestry Centre converts elite cultivars of the wild species into a commercially usable crop. In 2004, the company Yewcare began to plant Taxus chinensis in the Chinese provence of Yunan, currently covering more than 30 km2 in monoculture.

Chemical synthesis of paclitaxel was first achieved by Holton and Nicolau in 1994, but the low yield limit and the complexity of biosynthesis hampered its applicability. The alternative is production by semisynthesis via intermediates from the needles of the European yew.

Plant cell cultures represent an alternative, environmentally sustainable source of paclitaxel. Advantages of this method are growth of the material independent of its original location and not being subjected to seasonality or weather. Selection of cell lines, addition of precursors or optimization of culture conditions are strategies for the increase of paclitaxel yield in plant cultures. At the moment, Python Biotech is the largest producer of paclitaxel by this method.

In 1993, an endophytic taxol-producing fungus was found in Taxus, but fungal fermentation was shown to give low yields of paclitaxel. Nevertheless, Cytoclonal Pharmaceutis, Inc. patented the process and in 2001 signed a contract with Bristol-Myers Squibb for the development of new methodology based on microbial fermentation for paclitaxel and other new taxane therapeutics.

Demand, profits and future approaches

At the end of last century, worldwide sales for paclitaxel produced by Bristol-Myer Squibb climbed up to 1.5 billion dollars. Although there was a decrease in sales in the recent years, it is mainly due to patent expiration and increased generic production of the drug in Europe and Japan. The total market for paclitaxel remains well above 1 billion per year with continued expansion.

Suprageneric versions of paclitaxel were developed, such as nanoparticle albumin-bound paclitaxel (Abraxis Oncology's Abraxane) and polyglutamate paclitaxel (Cell Therapeutics' Xyotax). Their advantages are in terms of drug delivery and lower number of side-effects. Their sale growth remains steady, reflecting a growing market for paclitaxel and other derivatives of Taxus species.

In order to improve the yield of paclitaxel and other taxanes in cell cultures, efforts have been focused on assaying the biosynthetic activities of cultured cells. Some of the approaches include screening of high yielding cell lines, optimization of cultural conditions and production media, induction of secondary metabolite pathways and using a two-phase culture system. Future perspectives should be concentrated on the simultaneous use of empirical and rational approaches.


  4. Tabata H. Paclitaxel Production by Plant-Cell-Culture Technology. In: Zhong JJ, ed. Advances in Biochemical Engineering/Biotechonology - Biomanufacturing. Springer-Verlag Berlin Heidelberg, 2004; pp. 1-24.
  5. Khani S, Barar J, Movafeghi A, Omidi Y. Production of Anticancer Secondary Metabolites: Impacts of Bioprocess Engineering. In: Orhan IE, ed. Biotechnological Production of Plant Secondary Metabolites. Bentham Science Publishers, 2012; pp. 215-240.

Further Reading

Last Updated: Oct 21, 2014


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment